CTOs on the Move

Queens-Long Island Medical Group, P.C.

www.qlimg.com

 
Queens-Long Island Medical Group, P.C. is a Garden City, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.qlimg.com
  • 1000 Zeckendorf Blvd
    Garden City, NY USA 11530
  • Phone: 516.542.5500

Executives

Name Title Contact Details

Similar Companies

Sonic Innovations

Sonic Innovations, Inc. is a hearing aid company focused on the therapeutic aspects of hearing care. The Company designs, develops, manufactures and markets digital hearing aids. It has developed digital signal processing (DSP) technologies based on an

Savista

Savista is a prominent provider of healthcare revenue cycle management services. Savista partners with healthcare organizations to problem solve and deliver revenue cycle improvement services that enable their success, support their patients, and nurture their communities. We integrate knowledge and expertise of the revenue cycle to provide financial and operational performance benefits for healthcare organizations of any size. Our global organization of 4,000 colleagues partners with more than 330 US-based healthcare clients, delivering custom solutions to help solve their business challenges.

Vested Health

Vested Health is a Charleston, WV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MBI Solutions

MBI Solutions is a Dayton, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

HedgePath Pharmaceuticals

HedgePath Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer. The Company may also explore acquiring or licensing innovative therapeutics addressing unmet needs and orphan indications beyond cancer. We are focused on the development of therapies for more than one type of cancer, with initial emphasis in the U.S. market, based upon repurposing the currently marketed antifungal drug itraconazole for new indications in oncology.